This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
PLx Pharma Winddown Corp. Went Out of Business CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved for PLx Pharma Winddown Corp. CI
First Motion for Exclusivity Period Extension Approved For PLx Pharma Winddown Corp. CI
First Motion for Exclusivity Period Extension Filed by PLx Pharma Winddown Corp. CI
First Amended Disclosure Statement and Related Plan on Interim Basis Approved for PLx Pharma Winddown Corp. CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by PLx Pharma Winddown Corp. CI
Plx Pharma Winddown Corp. Announces Resignation of Natasha Giordano as Chief Executive Officer CI
Plx Pharma Winddown Corp. Announces Resignation of Rita O’Connor as Chief Financial Officer CI
Plx Pharma Winddown Corp. Announces Executive Changes CI
Combined Disclousre Statement and Liquidation Plan Filed by PLx Pharma Winddown Corp. CI
Motion for Asset Sale Approved for PLx Pharma Winddown Corp. CI
Notice for Auction Cancellation Filed PLx Pharma Winddown Corp. CI
Bidding Procedure Approved for PLx Pharma Inc. CI
PLx Pharma Inc.(OTCPK:PLXP.Q) dropped from S&P TMI Index CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from S&P TMI Index CI
Motion for Joint Administration Approved for PLx Pharma Inc. CI
Motion for Asset Sale Filed by PLx Pharma Inc. CI
Motion for Joint Administration Filed by PLx Pharma Inc. CI
PLx Pharma Inc. Filed for Bankruptcy CI
PLx Pharma Signs Stalking Horse Deal to Sell Assets to Greenwood Brands; Shares Jump After Hours MT
Top Midday Decliners MT
PLx Pharma Receives Notice of Delisting From Nasdaq MT
PLx Pharma Inc.(OTCPK:PLXP) dropped from NASDAQ Composite Index CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from Russell Microcap Growth Index CI
PLx Pharma Inc.(OTCPK:PLXP) dropped from Russell 3000E Growth Index CI
Chart PLx Pharma Winddown Corp.
More charts
PLx Pharma Winddown Corp., formerly PLx Pharma Inc., is a commercial-stage drug delivery platform technology company. The Company is focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent-protected PLxGuard technology. The Company has two Food and Drug Administration (FDA) approved products, VAZALORE 81 mg and VAZALORE 325 mg (VAZALORE), which are liquid-filled aspirin capsules for over-the-counter distribution (OTC). The Company markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation. It also screens additional compounds outside the NSAID category for possible development using its PLxGuard drug delivery platform.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. PLXP Stock
  4. News PLx Pharma Winddown Corp.
  5. PLx Pharma : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Target